LDCT stands for low-dose computed tomography, a type of CT scan that uses significantly less radiation than a standard CT to create detailed images of the lungs. It’s primarily used to screen for lung cancer in people at high risk, and it’s the only screening test proven to reduce lung cancer deaths. In the largest clinical trial to date, annual LDCT screening cut lung cancer mortality by 20% compared to standard chest X-rays.
How LDCT Differs From a Regular CT Scan
A standard diagnostic CT scan of the chest delivers roughly 7 to 8 millisieverts (mSv) of radiation, while a full abdominal CT averages around 10 mSv. An LDCT scan delivers approximately 1.5 to 2 mSv, which is comparable to the amount of natural background radiation you absorb from the environment over about six months. The images are detailed enough to detect small nodules in the lungs, often just a few millimeters across, that a chest X-ray would miss entirely.
The lower dose is achieved through adjustments to the scanner’s settings rather than any fundamentally different technology. The tradeoff is slightly grainier images compared to a full-dose scan, but for the purpose of spotting lung nodules, the image quality is more than sufficient. Advanced image processing techniques help compensate for the reduced radiation.
Who Should Get Screened
The U.S. Preventive Services Task Force recommends annual LDCT screening for adults aged 50 to 80 who have a 20 pack-year smoking history and either currently smoke or quit within the past 15 years. A “pack-year” means smoking an average of one pack per day for one year, so 20 pack-years could mean one pack a day for 20 years, two packs a day for 10 years, or any equivalent combination.
Screening should stop once you’ve been smoke-free for 15 years or if you develop a health condition that would make lung cancer treatment impractical. The recommendation applies only to people without symptoms. If you’re already experiencing signs like a persistent cough, chest pain, or unexplained weight loss, your doctor would likely order a full diagnostic CT instead.
What the Scan Is Like
The actual scan takes less than a minute. You lie on a table that slides through a large, ring-shaped scanner while holding your breath for a few seconds. There are no injections, no fasting requirements, and no sedation.
Before the scan, you’ll need to remove anything metal: jewelry, glasses, hearing aids, dentures. Wear clothing without metal buttons, snaps, or an underwire bra. If your clothes have too much metal, you’ll be asked to change into a gown. If you’ve recently had a respiratory infection, your screening may be delayed about a month to avoid confusing inflammation with something more concerning.
Understanding Your Results
LDCT results are reported using a standardized system called Lung-RADS, which assigns your scan a category from 1 to 4 based on what was found.
- Category 1 (Negative): No nodules detected. You return for your next annual screening in 12 months.
- Category 2 (Benign appearance): Small nodules were found but have a very low chance of being cancerous. You still return in 12 months for routine screening.
- Category 3 (Probably benign): A nodule was found that’s slightly larger or has features worth watching. A follow-up LDCT in 6 months is typically recommended.
- Category 4A (Suspicious): A nodule has characteristics that need closer evaluation. You’ll likely get a repeat scan in 3 months, and possibly additional imaging.
- Category 4B (Very suspicious): The findings are concerning enough that further testing or a tissue biopsy is recommended promptly.
The vast majority of people receive a Category 1 or 2 result and simply continue annual screening.
False Positives Are Common
One of the most important things to understand about LDCT screening is that it frequently flags findings that turn out not to be cancer. Across major studies, the median false-positive rate was about 20% on the first screening round and around 9.5% on subsequent rounds. In the landmark National Lung Screening Trial, roughly one in four baseline scans flagged something that required follow-up but ultimately wasn’t cancer.
Most false positives are small, benign nodules or spots caused by old infections, scar tissue, or inflammation. The follow-up process usually involves another LDCT scan a few months later to see if the nodule has changed. In a smaller percentage of cases, additional imaging like a PET scan (2.5% to 5.5% of screened individuals) or a biopsy (0.7% to 4.4%) may be needed. Among people who undergo a biopsy after screening, a significant portion, sometimes more than half, receive a benign result. Similarly, among those who have surgery for a screen-detected nodule, 6% to 45% turn out to have a non-cancerous finding.
This means that while LDCT screening saves lives, it also creates anxiety and sometimes invasive follow-up procedures for nodules that pose no real threat. Knowing this upfront can help you prepare mentally for the possibility of an unclear result that ultimately resolves on its own.
Coverage and Cost
Under the Affordable Care Act, private insurance plans are required to cover LDCT lung cancer screening without a copay for people who meet the eligibility criteria. Medicare Part B also covers annual screening with no out-of-pocket cost if you meet all of these conditions: you’re between 50 and 77, you have no symptoms of lung cancer, you have at least a 20 pack-year smoking history, you currently smoke or quit within the last 15 years, and your healthcare provider orders the test.
If you don’t meet the standard screening criteria or you’re uninsured, the out-of-pocket cost for an LDCT scan varies by facility but generally falls between $200 and $400. Some screening programs offer reduced rates, particularly at academic medical centers running lung cancer screening initiatives.
Why Early Detection Matters
Lung cancer kills more people than breast, colon, and prostate cancers combined, largely because it’s usually caught late. By the time symptoms appear, the cancer has often spread beyond the lungs. LDCT changes that equation by catching tumors when they’re small, localized, and far more treatable. The 20% mortality reduction seen in clinical trials reflects the difference between finding cancer at stage I, when five-year survival rates are high, versus stage III or IV, when they drop dramatically.
Despite its proven benefit, LDCT screening remains underused. Only a small fraction of eligible adults actually get screened each year. If you meet the criteria, annual screening is one of the most effective steps you can take to catch lung cancer early, when treatment is most likely to succeed.